A retrospective analysis of more than 400,000 U.S. births over nearly 6 years shows that delivery of triplets or more costs 20 times as much as a singleton. Published in The American Journal of Obstetrics and Gynecology, the report may be the first to look at medical expenses for both maternal and infant care associated with IVF-assisted pregnancy.
A retrospective analysis of more than 400,000 U.S. births over nearly 6 years shows that delivery of triplets or more costs 20 times as much as a singleton. Published in The American Journal of Obstetrics and Gynecology, the report may be the first to look at medical expenses for both maternal and infant care associated with IVF-assisted pregnancy.
The analysis, based on data from the Truven Health MarketScan Commercial Claims and Encounters, included 437,924 deliveries of live-born infants to women aged 19 to 45 from January 2005 to September 2010. Costs included payments made by insurers and patients. Expenses from 27 weeks before delivery to 1 month after delivery were included for mothers, and for infants, included all expenses until their first birthday. A generalized linear model was used to estimate adjusted cost.
Of the deliveries, 97.02% were singletons, 2.85% were twins, and 0.13% were triplets or higher. For singletons, the adjusted total all-cause health care cost was $21,458 (95% CI, $21,302-$21,614) per delivery, versus $104,831 (95% CI, $103,402-$106,280) for twins and $407,199 (95% CI, $384,984-$430,695) for triplets or more.
Incidence of systemic and localized comorbidity was significantly higher in women with multiple pregnancies than with singletons (P<.0001) and twins and triplets were more likely than singletons to have stayed in a neonatal intensive care unit (P<.0001).
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.
Pioglitazone outperforms metformin in IVF for PCOS-related infertility
May 6th 2024A recent double-blind, randomized clinical trial revealed a higher clinical pregnancy rate with pioglitazone compared to metformin in polycystic ovarian syndrome patients undergoing in vitro fertilization, suggesting potential for improved outcomes.
Read More
Reducing multifetal pregnancy through publicly funded IVF programs
April 26th 2024Learn how a mandatory elective single-embryo transfer policy in publicly funded in vitro fertilization programs significantly decreases multifetal pregnancy rates, offering insights into mitigating risks in assisted reproduction.
Read More
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More